4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients

European Journal of Cancer

Volumn 41, Issue 14, 2005, Pages 2184-2195

  Pasello, Michela ^a   Hattinger, Claudia Maria ^a   Stoico, Giuseppina ^a   Manara, Maria Cristina ^a   Benini, Stefania ^a   Geroni, Cristina ^b   Mercuri, Mario ^a   Scotlandi, Katia ^a   Picci, Piero ^a   Serra, Massimo ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Alkycyclines; Anthracyclines; Chemotherapy; Drug resistance; Osteosarcoma; P glycoprotein

Indexed keywords

4 DEMETHOXY 3' DEAMINO 3' AZIRIDINYL 4' METHYLSULFONYLDAUNORUBICIN; ANTINEOPLASTIC AGENT; CISPLATIN; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PNU 159548; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 25144520839     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.06.017     Document Type: Article

References (34)

1. B.P. Himelstein Osteosarcoma and other bone cancers Curr Opin Oncol 10 1998 326 333
2. V.H.C. Bramwell Osteosarcomas and other cancers of bone Curr Opin Oncol 12 2000 330 336
3. G. Bacci, S. Ferrari, and F. Bertoni Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report J Clin Oncol 18 2000 4016 4027
4. G. Bacci, S. Ferrari, and A. Longhi Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy Eur J Cancer 37 2001 32 38
5. O.S. Bruland, and A. Pihl On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy Eur J Cancer 33 1997 1725 1731
6. S.S. Bielack, B. Kempf-Bielack, and G. Delling Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 2002 776 790
7. S. Ferrari, F. Bertoni, and M. Mercuri Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 303 patients treated at the Rizzoli Institute Ann Oncol 12 2001 1145 1150
8. A.M. Davis, R.S. Bell, and P.J. Goodwin Prognostic factors in osteosarcoma: a critical review J Clin Oncol 12 1994 423 431
9. G. Saeter, I. Elomaa, and Y. Wahlqvist Prognostic factors in bone sarcomas Acta Orthop Scand 273 1997 156 160
10. G. Bacci, S. Ferrari, and F. Bertoni Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy Clin Orthop 386 2001 186 196
11. M.A. Smith, R.S. Ungerleider, and M.E. Horowitz Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma J Natl Cancer Inst 83 1991 1460 1470
12. S.M. Blaney, M.A. Smith, and J.L. Grem Osteosarcoma in adolescents and young adults: new developments and controversies. Doxorubicin: role in the treatment of osteosarcoma 1993 Kluwer Academic Publishers Boston p. 55-73
13. V.H. Bramwell The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma Semin Oncol 24 1997 561 571
14. N. Baldini, K. Scotlandi, and G. Barbanti-Bròdano Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome N Eng J Med 333 1995 1380 1385
15. H.S. Chan, T.M. Grogan, and G. Haddad P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy J Natl Cancer Inst 89 1997 1706 1715
16. M. Serra, K. Scotlandi, and G. Reverter-Branchat Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities J Clin Oncol 21 2003 536 542
17. E.E. Pakos, and J.P. Ioannidis The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis Cancer 98 2003 581 589
18. S.E. Bates Drug resistance: still on the learning curve Clin Cancer Res 5 1999 3346 3348
19. C. Geroni, M. Ripamonti, and C. Arrigoni Pharmacological and toxicological aspects of 4-demethoxy-3′-deamino-3′-aziridinyl- 4′-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent Cancer Res 61 2001 1983 1990
20. S. Marchini, G. Damia, and M. Broggini 4-Demethoxy-3′-deamino- 3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms Cancer Res 61 2001 1991 1995
21. P. Della Torre, A. Podesta, and A.R. Imondi PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential Cancer Chemother Pharmacol 47 2001 355 360
22. S. Benini, N. Baldini, and M.C. Manara Redundancy of autocrine loops in human osteosarcoma cells Int J Cancer 80 1999 581 588
23. M. Serra, K. Scotlandi, and M.C. Manara Establishment and characterization of multidrug-resistant human osteosarcoma cell lines Anticancer Res 13 1993 323 329
24. K. Scotlandi, M. Serra, and M.C. Manara Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin Int J Cancer 58 1994 95 101
25. C.M. Hattinger, G. Reverter-Branchat, and D. Remondini Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques Eur J Cell Biol 82 2003 483 493
26. M. Serra, G. Reverter-Branchat, and D. Maurici Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells Ann Oncol 15 2004 151 160
27. M.J. De Jonge, J. Verweij, and A. Van Der Gaast Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours Eur J Cancer 38 2002 2407 2415
28. D. Moneta, C. Geroni, and O. Valota Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′- methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation Eur J Cancer 39 2003 675 683
29. Y. Kano, T. Ohnuma, and T. Okano Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture Cancer Res 48 1988 351 356
30. N. Baldini, K. Scotlandi, and M. Serra Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma J Cancer Res Clin Oncol 119 1992 121 126
31. N. Baldini, K. Scotlandi, and M. Serra Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution Eur J Cell Biol 68 1995 226 239
32. N. Baldini, K. Scotlandi, and M. Serra P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy J Orthop Res 17 1999 629 632
33. S. Marchini, O. Gonzalez Paz, and M. Ripamonti Sequence-specific DNA interactions by novel alkylating anthracycline derivatives Anticancer Drug Des 10 1995 641 653
34. H. Calvert An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents Semin Oncol 26 1999 3 10